格隆汇1月21日丨益佰制药（维权）(600594.SH)公布，经公司财务部门初步测算，公司预计2025年度实 现归属于母公司所有者的净利润为-34,200万元到-28,500万元，将出现亏损。公司预计2025年度实现归 属于母公司所有者的扣除非经常性损益后的净利润为-33,600万元到-28,000万元。报告期内，公司主要 产品销售减少，导致公司收入预计下降14%；公司成本费用虽预计下降18%，但成本费用金额仍大于收 入金额，导致本期亏损。 ...

证券代码：600594 证券简称：益佰制药 公告编号：2026-002 贵州益佰制药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本期业绩预告适用净利润为负值的情形 业绩预告相关的主要财务数据情况： （三）本期业绩预告情况未经注册会计师审计。 二、上年同期经营业绩和财务状况 （一）公司 2024 年度利润总额：-33,252 万元。归属于母公司所有者的净 贵州益佰制药股份有限公司（以下简称"公司"）预计 2025 年度实现归属于 母公司所有者的净利润为-34,200 万元到-28,500 万元，将出现亏损。 公司预计 2025 年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-33,600 万元到-28,000 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经公司财务部门初步测算，公司预计 2025 年度实现归属于母公司所有者 的净利润为-34,200 万元到-28 ...

益佰制药公告，益佰制药发布2025年度业绩预告，预计归属于上市公司股东的净利润亏损2.85亿元-3.42 亿元，将出现亏损。上年同期为亏损31722万元。报告期内，公司主要产品销售减少导致收入下降，成 本费用虽有所下降但仍高于收入；同时预计计提商誉减值准备11000万元至13200万元，进一步加剧亏 损。 ...

Core Viewpoint - Yibai Pharmaceutical (600594) expects to report a net loss attributable to shareholders for the fiscal year 2025, with specific figures yet to be disclosed [1] Financial Performance - The company's financial department has conducted preliminary assessments confirming that operating performance will face losses [1] - Yibai Pharmaceutical will expedite its financial accounting processes and aims to disclose the 2025 performance forecast within the stipulated timeframe [1] - The final financial data will be based on the formally disclosed audited annual report [1]

Group 1 - The company, Guizhou Yibai Pharmaceutical Co., Ltd., expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss in operating performance [1] - The company will adhere to the relevant regulations of the Shanghai Stock Exchange and expedite its financial accounting process to disclose the 2025 annual performance forecast within the stipulated timeframe [1] - Final financial data will be based on the officially disclosed audited annual report for 2025 [1] Group 2 - The announcement emphasizes the importance of accurate and complete information disclosure, with the board of directors ensuring there are no false records or misleading statements [1] - Designated media for information disclosure include Securities Times, Securities Daily, Shanghai Securities Journal, China Securities Journal, and the Shanghai Stock Exchange website [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) announced that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operational loss for the company in that year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) announced that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operational loss for the company in that year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a negative net profit attributable to shareholders for the fiscal year 2025, indicating an operational loss for the company [1] Financial Performance - The company’s financial department has conducted preliminary calculations, forecasting a loss for the fiscal year 2025 [1] - Yibai Pharmaceutical will adhere to the regulations set forth by the Shanghai Stock Exchange and expedite its financial accounting processes [1] - The final financial data will be based on the officially disclosed audited annual report for 2025 [1]

Core Viewpoint - Yibai Pharmaceutical (600594) announced that it expects a negative net profit for the fiscal year 2025, indicating an anticipated operational loss for the year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1] - Yibai Pharmaceutical will adhere to the Shanghai Stock Exchange listing rules and expedite its financial accounting process [1] Future Disclosure - The company commits to disclosing the 2025 annual performance forecast within the stipulated timeframe [1] - The final financial data will be based on the officially disclosed audited annual report for 2025 [1]

Financial Performance Expectations - Guizhou Yibai Pharmaceutical Co., Ltd. expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss[1] - Final financial data will be based on the officially disclosed audited annual report for 2025[1] Compliance and Reporting - The company is accelerating its financial accounting processes to comply with the Shanghai Stock Exchange regulations and will disclose the 2025 performance forecast within the stipulated timeframe[1]